Bazedoxifene as a Potential Cancer Therapeutic Agent Targeting IL-6/GP130 Signaling

Targeting the interleukin-6 (IL-6)/glycoprotein 130 (GP130) signaling pathway holds significant promise for cancer therapy given its essential role in the survival and progression of various cancer types. We have identified that bazedoxifene (BZA), a Food and Drug Administration (FDA)-approved drug...

Full description

Bibliographic Details

Published in:	Current Oncology
Main Authors:	Changyou Shi, Taylor Bopp, Hui-Wen Lo, Katherine Tkaczuk, Jiayuh Lin
Format:	Article
Language:	English
Published:	MDPI AG 2024-09-01
Subjects:	Bazedoxifene GP130 IL-6 STAT3 cancer therapy
Online Access:	https://www.mdpi.com/1718-7729/31/10/426